Dxna, LLC

Dxna, LLC specializes in thermal cycler nucleic acid amplification analysers intended for in vitro diagnostic (IVD) use in laboratory environments. These devices perform nucleic acid amplification, a key process in detecting genetic material from pathogens or other targets. The company’s products, such as the GeneSTAT system, are designed to automate and streamline molecular diagnostics for clinical or research applications.

Dxna, LLC is based in the United States, which means its devices are subject to FDA regulatory requirements. The company’s products fall under the FDA’s jurisdiction, requiring compliance with U.S. regulations for IVD devices, including classification, premarket authorisation processes, and post-market reporting.

Dxna, LLC’s devices are classified as Class II under FDA regulations. This classification indicates moderate risk and requires specific controls, such as premarket notifications (510(k)) or the De Novo pathway, to demonstrate safety and effectiveness before commercialisation. Class II status ensures that these devices undergo rigorous review to balance innovation with patient safety.

Dxna, LLC’s devices are listed in the FDA’s 510(k) database and the FDA’s Unique Device Identifier (UDI) database. The 510(k) database provides details on premarket submissions, while the UDI database includes device identification information (like model numbers and labels) for traceability and compliance tracking. These listings help healthcare providers, regulators, and researchers verify authorised products.

The 510(k) pathway is used for devices that are substantially equivalent to legally marketed predicates, requiring the manufacturer to demonstrate similarity in design, performance, and intended use. The De Novo pathway applies when no predicate exists, and the FDA evaluates the device’s safety and effectiveness through a more detailed review. Both pathways ensure that Dxna’s devices meet FDA standards before entering the market, but they serve different scenarios based on existing technology.